Evidence map›Paper›PMID 37798085›Full record

SynthesisGut2023

Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people.

Zhenqiu Liu, Chunqing Lin, Xianhua Mao, Chengnan Guo, Chen Suo, Dongliang Zhu, Wei Jiang, Yi Li, Jiahui Fan, Ci Song and 5 more

Registry-linked trialOpen access · hybridAbstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06184347 (A Prospective and Observational Investigation on Chronic Hepatitis B Virus Infection and Related Liver Diseases Via Systematic Screening in General Population), which is not on this map. Cited by 95 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 4 pooled it
26.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06184347 unknown statusnot on this mapstarted 2024, after this paper: background citation

A Prospective and Observational Investigation on Chronic Hepatitis B Virus Infection and Related Liver Diseases Via Systematic Screening in General Population

Typeobservational_patient_registrySponsorNanfang Hospital, Southern Medical UniversityRan2024 to 2025Enrolled3,700,000ConditionsHBV Infection, Chronic Hepatitis B, Cirrhosis, HCCArmsRapid tests for HBsAg
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 4 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Zhenqiu LiuState Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China.
Chunqing LinNational Clinical Research Center for Cancer, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xianhua MaoDepartment of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region, China.
Chengnan GuoDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.ORCID 0000-0003-2275-3575
Chen SuoFudan University Taizhou Institute of Health Sciences, Taizhou, China.
Dongliang ZhuDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Wei JiangState Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China.
Yi LiDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Jiahui FanState Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China.
Ci SongDepartment of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Tiejun ZhangFudan University Taizhou Institute of Health Sciences, Taizhou, China.
Li JinState Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China.
Catherine De MartelEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Gary M CliffordEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France xingdongchen@fudan.edu.cn cliffordg@iarc.who.int.
Xingdong ChenState Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China xingdongchen@fudan.edu.cn cliffordg@iarc.who.int.ORCID 0000-0003-3763-160X
Fudan University · CNCentre international de recherche sur le cancer · FRChinese Academy of Medical Sciences & Peking Union Medical College · CNNanjing Medical University · CNUniversity of Hong Kong · HK

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectiveChina concentrates a large part of the global burden of HBV infection, playing a pivotal role in achieving the WHO 2030 global hepatitis elimination target.

methodsWe searched for studies reporting HBV surface antigen (HBsAg) seroprevalence in five databases until January 2023. Eligible data were pooled using a generalised linear mixed model with random effects to obtain summary HBsAg seroprevalence. Linear regression was used to estimate annual percentage change (APC) and HBsAg prevalence in 2021.

results3740 studies, including 231 million subjects, were meta-analysed. HBsAg seroprevalence for the general population decreased from 9.6% (95% CI 8.4 to 10.9%) in 1973-1984 to 3.0% (95% CI 2.1 to 3.9%) in 2021 (APC=-3.77; p<0.0001). Decreases were more pronounced in children <5 years (APC=-7.72; p<0.0001) and 5-18 years (-7.58; p<0.0001), than in people aged 19-59 years (-2.44; p<0.0001), whereas HBsAg seroprevalence increased in persons ≥60 years (2.84; p=0.0007). Significant decreases were observed in all six major Chinese regions, in both men (APC=-3.90; p<0.0001) and women (-1.82; p<0.0001) and in high-risk populations. An estimated 43.3 million (95% uncertainty interval 30.7-55.9) persons remained infected with HBV in China in 2021 (3.0%), with notable heterogeneity by region (<1.5% in North China to>6% in Taiwan and Hong Kong) and age (0.3%, 1.0%, 4.7% and 5.6% for <5 years, 5-18 years, 19-59 years and

conclusionsChina has experienced remarkable decreases in HBV infection over the last four decades, but variations in HBsAg prevalence persist in subpopulations. Ongoing prevention of HBV transmission is needed to meet HBV elimination targets by 2030. TRIAL REGISTRATION NUMBER: PROSPERO (CRD42021284217).

Indexed as

Hepatitis BHepatitis B, ChronicChildChinaFemaleHepatitis B Surface AntigensHepatitis B virusHumansMalePrevalenceSeroepidemiologic StudiesHepatitis B Surface AntigensHEPATITIS BMETA-ANALYSIS

Identifiers

PMID37798085
PMCPMC10715530
OpenAlexW4387378669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.